A recap of the top women's health headlines from October 2026, including FDA approval of pritelivir for refractory HSV, ACOG's new menopause guideline, and more.
News|Articles|October 1, 2026
A recap of top FDA & regulatory news from September 2026
Author(s)Joshua Fitch, Senior Editor
Fact checked by: Benjamin P. Saylor
A recap of Contemporary OB/GYN's top FDA and regulatory news from September 2026.
Advertisement
Advertisement
September brought a strong slate of FDA and regulatory developments across women’s health, from a supply update on a widely used menopause therapy to a priority review designation for a non-hormonal VMS treatment. Below, the Contemporary OB/GYN team recaps the top FDA-related stories from the month.
Related to this article
Patients with 3 or more adverse pregnancy outcomes had lower odds of postpartum contraceptive use in a PRAMS analysis of 222,412 individuals.
Kanchi Chadha, MD, FACOG, MSCP, supports reconsidering MHT boxed warnings but says the FDA cited no study behind the change.
Soma Mandal, MD, MSCP, says removing MHT boxed warnings is overdue but calls for transparency on the FDA's product-specific rationale.
Susan Reed, MD, MPH, MS, and Calbeth C. Alaribe, DMSc, MPH, PA-C, CPCHE, weigh in on FDA boxed warning removals for menopausal hormone therapy.
The FDA granted accelerated approval to Voceryq to reduce papilloma excision surgeries in adults with recurrent respiratory papillomatosis.
The October 30 update from the FDA follows the February 12, 2026 labeling changes to 6 menopausal hormone therapy products in which the agency also removed safety-related boxed warnings.
Joint guidance from the AHA, AAP, ACOG, and SMFM organizes cardiovascular prevention for girls and women around 4 female life stages.
Advertisement
Advertisement